Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPC) for Cimalgex 8 mg / 30 mg / 80 mg Chewable Tablets for Dogs has been updated:
- Polyuria and/or polydipsia may be observed on rare occasions and severe gastrointestinal and renal adverse events may be fatal.
All updates to SPCs other than template changes, are published in the medicine updates section of VMD Connect.
Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.
No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6).
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
